Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 10
2003 3
2004 14
2005 19
2006 36
2007 54
2008 70
2009 60
2010 71
2011 86
2012 134
2013 171
2014 238
2015 355
2016 505
2017 589
2018 617
2019 623
2020 675
2021 538
Text availability
Article attribute
Article type
Publication date

Search Results

4,298 results
Results by year
Filters applied: . Clear all
Page 1
The PCSK9 decade.
Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. Lambert G, et al. J Lipid Res. 2012 Dec;53(12):2515-24. doi: 10.1194/jlr.R026658. Epub 2012 Jul 17. J Lipid Res. 2012. PMID: 22811413 Free PMC article. Review.
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL receptor. ...Moreover, we briefly describe the clinical phenotypes encountered in carrier
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, Xie L, Huang Q, Li F, Li CY. Liu X, et al. Nature. 2020 Dec;588(7839):693-698. doi: 10.1038/s41586-020-2911-7. Epub 2020 Nov 11. Nature. 2020. PMID: 33177715 Free PMC article.
Many efforts are therefore underway to identify new approaches that enhance such immune 'checkpoint' therapy(3-5) (so called because its aim is to block proteins that inhibit checkpoint signalling pathways in T cells, thereby freeing those immune cells to target cancer cells). He …
Many efforts are therefore underway to identify new approaches that enhance such immune 'checkpoint' therapy(3-5) (so called because its aim …
Inhibiting PCSK9 - biology beyond LDL control.
Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Stoekenbroek RM, et al. Nat Rev Endocrinol. 2018 Dec;15(1):52-62. doi: 10.1038/s41574-018-0110-5. Nat Rev Endocrinol. 2018. PMID: 30367179 Review.
Although therapeutic PCSK9 inhibition could theoretically have undesired effects by interfering with these non-cholesterol-related processes, studies of individuals with genetically determined reduced PCSK9 function and clinical trials of PCSK9 inhibitors hav …
Although therapeutic PCSK9 inhibition could theoretically have undesired effects by interfering with these non-cholesterol-related pr …
Hypercholesterolemia: The role of PCSK9.
Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Melendez QM, et al. Arch Biochem Biophys. 2017 Jul 1;625-626:39-53. doi: 10.1016/j.abb.2017.06.001. Epub 2017 Jun 3. Arch Biochem Biophys. 2017. PMID: 28587771 Review.
The magnitude of PCSK9's involvement in the onset of these metabolic abnormalities appears to be associated with age, sex, and ethnic background. ...Herein, we will review the functions and regulatory mechanisms of PCSK9. The effects of PCSK9 on the LD …
The magnitude of PCSK9's involvement in the onset of these metabolic abnormalities appears to be associated with age, sex, and …
PCSK9 inhibition in the management of familial hypercholesterolemia.
Ogura M. Ogura M. J Cardiol. 2018 Jan;71(1):1-7. doi: 10.1016/j.jjcc.2017.07.002. Epub 2017 Aug 5. J Cardiol. 2018. PMID: 28784313 Free article. Review.
Since PCSK9 degrades LDL receptor protein, inhibiting PCSK9 will be an effective strategy. Evolocumab and alirocumab, anti-PCSK9 antibodies that inhibit binding between PCSK9 and LDL receptors, are now available in Japan. ...
Since PCSK9 degrades LDL receptor protein, inhibiting PCSK9 will be an effective strategy. Evolocumab and alirocumab, anti- …
PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1.
Ding Z, Pothineni NVK, Goel A, Lüscher TF, Mehta JL. Ding Z, et al. Cardiovasc Res. 2020 Apr 1;116(5):908-915. doi: 10.1093/cvr/cvz313. Cardiovasc Res. 2020. PMID: 31746997 Review.
PCSK9 inhibitors also reduce the extent of atherosclerosis. Recent studies show that PCSK9 is secreted by vascular endothelial cells, smooth muscle cells, and macrophages. ...PCSK9 also interacts with oxidized-LDL receptor-1 (LOX-1) in a mutually facilitative
PCSK9 inhibitors also reduce the extent of atherosclerosis. Recent studies show that PCSK9 is secreted by vascular endothelial
An Update on the Role of PCSK9 in Atherosclerosis.
Yurtseven E, Ural D, Baysal K, Tokgözoğlu L. Yurtseven E, et al. J Atheroscler Thromb. 2020 Sep 1;27(9):909-918. doi: 10.5551/jat.55400. Epub 2020 Jul 23. J Atheroscler Thromb. 2020. PMID: 32713931 Free PMC article. Review.
Monoclonal PCSK9 antibodies that block the effects of PCSK9 on LDL receptors demonstrated beneficial results in cardiovascular outcome trials. ...This review focuses on the molecular roles of PCSK9 in atherosclerotic plaque formation....
Monoclonal PCSK9 antibodies that block the effects of PCSK9 on LDL receptors demonstrated beneficial results in cardiovascular …
PCSK9: A novel inflammation modulator in atherosclerosis?
Tang ZH, Li TH, Peng J, Zheng J, Li TT, Liu LS, Jiang ZS, Zheng XL. Tang ZH, et al. J Cell Physiol. 2019 Mar;234(3):2345-2355. doi: 10.1002/jcp.27254. Epub 2018 Sep 24. J Cell Physiol. 2019. PMID: 30246446 Review.
However, in addition to the effect of PCSK9 on elevating blood LDL-c levels, accumulating evidence shows that PCSK9 plays an important role in inflammation, likely representing another major mechanism for PCSK9 to promote atherosclerosis. ...A better understa …
However, in addition to the effect of PCSK9 on elevating blood LDL-c levels, accumulating evidence shows that PCSK9 plays an i …
PCSK9 signaling pathways and their potential importance in clinical practice.
Wiciński M, Żak J, Malinowski B, Popek G, Grześk G. Wiciński M, et al. EPMA J. 2017 Aug 14;8(4):391-402. doi: 10.1007/s13167-017-0106-6. eCollection 2017 Dec. EPMA J. 2017. PMID: 29209441 Free PMC article. Review.
PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism. ...Discoveries in drugs development are focused on blocking PCSK9 on different levels. For example, silencing messenger RNA (mRNA of PCSK9) is a new alternative against h
PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism. ...Discoveries in drugs development are focu
PCSK9: a key modulator of cardiovascular health.
Seidah NG, Awan Z, Chrétien M, Mbikay M. Seidah NG, et al. Circ Res. 2014 Mar 14;114(6):1022-36. doi: 10.1161/CIRCRESAHA.114.301621. Circ Res. 2014. PMID: 24625727 Review.
Surprisingly, in a nonenzymatic fashion, PCSK9 enhances the intracellular degradation of all its target proteins. ...This review will address the biochemical, genetic, and clinical aspects associated with PCSK9's biology and pathophysiology in cells, rodent a …
Surprisingly, in a nonenzymatic fashion, PCSK9 enhances the intracellular degradation of all its target proteins. ...This review will …
4,298 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page